Lumos Pharma — Q1 2020 Earnings Presentation
12 slides from Lumos Pharma's earnings presentation, May 28, 2020
Slide 1: First Quarter 2020 Financial Results
First Quarter 2020 Financial Results May 28, 2020
Slide 2: Lumos Pharma Q1 2020 Conference Call Agenda
Lumos Pharma Q1 2020 Conference Call • Lisa Miller, Director of Investor Relations • Rick Hawkins, CEO Agenda • John McKew, PhD, COO & CSO • Eugene Kennedy, MD, CMO • Carl Langren, CFO 2
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The
Slide 4: Overview of Company
Overview of Company • Late-stage novel therapeutic asset, LUM-201, with validating Phase 2b trial in Pediatric Growth Hormone Deficiency (PGHD) anticipated to begin prior to the end of 2020 • Established and sizable overall market targeted of over $1B*, with potential to disrupt current treatment re
Slide 5: Experienced Management
Experienced Management Experienced management team with significant clinical development and commercial experience • Richard Hawkins – Chairman, CEO & President of Lumos Pharma, developer of Growth Hormone (GH) Receptor Antagonist for Acromegaly at Sensus (sold to Pfizer). Built one of the first con
Slide 6: PGHD and Standard of Care
PGHD and Standard of Care • PGHD occurs due to inadequate secretion of growth hormone by the pituitary gland during childhood • PGHD can be either hereditary or acquired, although the majority of cases have unknown causes (idiopathic) versus - Lack of physical growth is the most obvious manifestatio
Slide 7: LUM-201 Mechanism of Action
LUM-201 Mechanism of Action GHSR1a Hypothalamus • Oral LUM-201 is a growth LUM- hormone (GH) secretagogue SST GHRH 201 • Acts as an agonist of GH GHSR1a Secretagogue Receptor Pituitary (GHSR1a) to stimulate GH release1 • LUM-201 has been observed to GH increase the amplitude of endogenous pulsatile
Slide 8: Targeted PGHD Population
Targeted PGHD Population PEM-Positive: Included PEM-Negative: Excluded GHSR1a GHSR1a Hypothalamus HypothalamusIGF-1 SST GHRH LUM- SST GHRH LUM- 201 201 GHSR1a GHSR1a Pituitary Pituitary GH GH IGF-1 • Functional but reduced HP-GH axis • Non-functional HP-GH axis - Able to secrete some, but insufficie
Slide 9: Clinical Development Outline for PGHD
Clinical Development Outline for PGHD • Two main goals set for Phase 2b - Prospectively confirm the utility of PEM strategy - Determine the optimal dose for Phase 3 registration trial • Phase 2b PGHD clinical trial design - Three dose levels of LUM-201 (0.8, 1.6, 3.2 mg/kg) - Positive control arm of
Slide 10: LUM-201: Other Potential Rare Endocrine Disorders
LUM-201: Other Potential Rare Endocrine Disorders • Beyond PGHD, Prader-Willi Syndrome Small for Gestational Age rhGH FDA approved in 2000 rhGH FDA approved in 2001 Lumos Pharma also plans to investigate LUM-201 for other rare endocrine disorders, for which rhGH has been approved Idiopathic Short St
Slide 11: Secure Projected Cash Position
Secure Projected Cash Position Metric Position Cash balance on March 31, 2020 $85.8 million Funds from monetization of 60% interest in Additional non-dilutive resources expected value of PRV Projected cash use per quarter through 2020 ~ $6.5 to $7.5 million Shares outstanding as of April 27, 20201 ~
Slide 12: Lumos Pharma: Summary of Investment Thesis
Lumos Pharma: Summary of Investment Thesis Lumos Pharma • Lead program, LUM-201, with potential to be the (NASDAQ:LUMO) first oral growth hormone secretagogue therapy Transforming Lives for PGHD with Rare Focus • Opportunity to disrupt established and sizable market • Management team with extensive